Actively Recruiting

Age: 14Years - 80Years
All Genders
NCT06530316

RET Inhibitor for Neoadjuvant Therapy in Locally Advanced RET-altered Thyroid Cancer

Led by Fudan University · Updated on 2024-08-02

48

Participants Needed

1

Research Sites

284 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study is a multicenter observational study. Patients receive neoadjuvant therapy with RET inhibitors in the real world, and those who can undergo surgery after neoadjuvant therapy receive surgical treatment. The aim of the study is to determine the efficacy and safety of RET inhibitors for neoadjuvant therapy in locally advanced RET-altered thyroid cancer.

CONDITIONS

Official Title

RET Inhibitor for Neoadjuvant Therapy in Locally Advanced RET-altered Thyroid Cancer

Who Can Participate

Age: 14Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients voluntarily join this study and sign an informed consent form
  • Age 14 years or older, any gender
  • Locally advanced thyroid cancer diagnosed by histopathology, including papillary, medullary, follicular, poorly differentiated thyroid carcinoma, etc
  • RET alterations including fusion and mutations
  • Locally advanced thyroid cancer meeting at least one of: estimated surgical difficulty with inability to achieve R0/1 resection; T4 thyroid cancer with tumor or lymph node infiltration beyond thyroid capsule; resectable probability less than 80% based on CT imaging
  • At least one measurable lesion
  • For patients with distant metastasis, surgical benefit must be determined by researchers
  • Willing to undergo tumor tissue biopsy or surgery during enrollment and withdrawal
  • Normal function of major organs
Not Eligible

You will not qualify if you...

  • Previous use of RET inhibitors
  • Multiple factors affecting oral medication absorption, such as inability to swallow, nausea, vomiting, chronic diarrhea, or intestinal obstruction
  • Refusal to undergo tumor tissue biopsy or surgery
  • Unsuitable for RET inhibitors or surgery

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Fudan Univeristy Shanghai Cancer Center

Shanghai, China

Actively Recruiting

Loading map...

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here